Key result
Trimetazidine significantly reduced markers of myocardial injury, including Troponin T at ≤12 hours postoperatively (SMD -6.51), compared to control in patients undergoing CABG surgery.
Why the study?
Myocardial injury markers are elevated after CABG, and the cardioprotective role of the anti-ischemic agent trimetazidine on postoperative myocardial preservation remained to be systematically analysed.
Does trimetazidine reduce postoperative myocardial injury markers in patients undergoing CABG?
Meta-Analysis
Randomized
Does trimetazidine reduce postoperative myocardial injury markers in patients undergoing CABG?
Standardized Mean Difference: -6.51 (95% CI -9.75–-3.27)
p-value: p=<0.00001
Trimetazidine therapy may provide cardioprotective effects during CABG by significantly reducing postoperative markers of myocardial injury such as TnT, CK-MB, and CK.
Trimetazidine reduces post-CABG myocardial injury markers; confirms perioperative cardioprotection in RCT meta-analysis.
Aims: Increased biochemicals such as Troponin T, CKMB, and CK from myocardial injury are side effects of CABG. Trimetazidine is an anti-ischemic agent that can also have a cardioprotective. We conducted a systematic review and meta-analysis to analyse the role of trimetazidine therapy on postoperative myocardial preservation in CABG. Methods: The research instrument used was RCT test articles that have been published in the PubMed, Cochrane, and Google Scholar databases in 2013 and 2023. We were classified into two group analyses based on sampling time (at least ≤12 or >12 hours after CABG). Results: Five RCTs were finally included in the meta-analysis. Significant differences in TnT, CK-MB, and CK were found between trimetazidine-treated CABG patients and control CABG patients (p < 00001) in the subgroup examinations conducted ≤12 and >12 post-CABG, indicating significantly lower postoperative TnT, CK-MB, and CK levels in trimetazidine-treated CABG patients compared with control CABG patients. Conclusion: Myocardial preservation of CABG by comparing the effects of trimetazidine and placebo by assessing several levels of myocardial damage such as TnT, CK-MB, and CK was significantly lower in CABG patients treated with trimetazidine compared with control CABG patients.
No takes yet. Share an insight, caveat, or question.
Sabri et al. (2023) conducted a meta-analysis in Coronary Artery Bypass Grafting (CABG) surgery. Trimetazidine vs. Placebo or conventional drugs was evaluated on Troponin T (TnT) levels ≤12 hours postoperatively (SMD -6.51, 95% CI -9.75 to -3.27, p=<0.00001). Trimetazidine significantly reduced markers of myocardial injury, including Troponin T at ≤12 hours postoperatively (SMD -6.51), compared to control in patients undergoing CABG surgery.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: